P2X Purinoceptor 3 (P2RX3) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

P2X purinoceptor 3 is a protein encoded by the P2RX3 gene. It belongs to the family of purinoceptors. This receptor functions as a ligand-gated ion channel and transduce ATP-evoked nociceptor activation. This receptor is important for peripheral pain responses, and also participates in pathways controlling urinary bladder volume reflexes.

The P2X Purinoceptor 3 drugs in development market research report provides an in-depth analysis of P2X Purinoceptor 3 (P2RX3) targeted pipeline therapeutics. The report provides comprehensive information on the P2X Purinoceptor 3 (P2RX3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases.

What are the therapy areas of the P2X Purinoceptor 3 pipeline drugs market?

The therapy areas of the P2X Purinoceptor 3 pipeline drugs market are the central nervous system, respiratory, dermatology, genitourinary system and sex hormones, ophthalmology, and women’s health.

P2X Purinoceptor 3 pipeline drugs market, by therapy areas

P2X Purinoceptor 3 pipeline drugs market, by therapy areas

For more therapy area insights, download a free report sample

What are the indications of the P2X Purinoceptor 3 pipeline drugs market?

Some of the indications of the P2X Purinoceptor 3 pipeline drugs market are chronic cough, pain, cough, neuropathic pain (neuralgia), inflammatory pain, pruritus, visceral pain, Alzheimer’s disease, diabetic neuropathic pain, and endometriosis.

P2X Purinoceptor 3 pipeline drugs market, by indications

P2X Purinoceptor 3 pipeline drugs market, by indications

For more indication insights, download a free report sample

What are the mechanisms of action of the P2X Purinoceptor 3 pipeline drugs market?

The mechanism of action of the P2X Purinoceptor 3 pipeline drugs market is P2X Purinoceptor 3 Antagonist.

What are the routes of administration in the P2X Purinoceptor 3 pipeline drugs market?

The route of administration in the P2X Purinoceptor 3 pipeline drugs market is oral.

What are the molecule types in the P2X Purinoceptor 3 pipeline drugs market?

The molecule types in the P2X Purinoceptor 3 pipeline drugs market are small molecule, monoclonal antibody, and peptide.

P2X Purinoceptor 3 pipeline drugs market, by molecule types

P2X Purinoceptor 3 pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Which are the key companies in the P2X Purinoceptor 3 pipeline drugs market?

Some of the key companies in the P2X Purinoceptor 3 pipeline drugs market are Merck & Co Inc, Asana BioSciences LLC, Bayer AG, Beijing Tide Pharmaceutical Co Ltd, BELLUS Health Inc, Future Analgesics, Integral Molecular Inc, Neurim Pharmaceuticals Ltd, Ossianix Inc, Shionogi & Co Ltd, and Sino Biopharmaceutical Ltd.

P2X Purinoceptor 3 pipeline drugs market, by key companies

P2X Purinoceptor 3 pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report scope

Therapy Areas Central Nervous System, Respiratory, Dermatology, Genitourinary System and Sex Hormones, Ophthalmology, and Women’s Health
Indications Chronic Cough, Pain, Cough, Neuropathic Pain (Neuralgia), Inflammatory Pain, Pruritus, Visceral Pain, Alzheimer’s Disease, Diabetic Neuropathic Pain, and Endometriosis
Mechanisms of Action P2X Purinoceptor 3 Antagonist
Routes of Administration Oral
Molecule Types Small Molecule, Monoclonal Antibody, and Peptide
Key Companies Asana BioSciences LLC, Bayer AG, Beijing Tide Pharmaceutical Co Ltd, BELLUS Health Inc, Future Analgesics, Integral Molecular Inc, Merck & Co Inc, Neurim Pharmaceuticals Ltd, Ossianix Inc, Shionogi & Co Ltd, and Sino Biopharmaceutical Ltd

This report provides:

  • A snapshot of the global therapeutic landscape of P2X Purinoceptor 3 (P2RX3).
  • Reviews of pipeline therapeutics for P2X Purinoceptor 3 (P2RX3) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Key players involved in P2X Purinoceptor 3 (P2RX3) therapeutics and enlists all their major and minor projects.
  • Assessment of P2X Purinoceptor 3 (P2RX3) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • Summaries of all the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for P2X Purinoceptor 3 (P2RX3).

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 3 (P2RX3)Identify the use of drugs for target identification and drug repurposing.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 3 (P2RX3) development landscape.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Asana BioSciences LLC
Bayer AG
Beijing Tide Pharmaceutical Co Ltd
BELLUS Health Inc
Future Analgesics
Integral Molecular Inc
Merck & Co Inc
Neurim Pharmaceuticals Ltd
Ossianix Inc
Shionogi & Co Ltd
Sino Biopharmaceutical Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

P2X Purinoceptor 3 (P2RX3) – Overview

P2X Purinoceptor 3 (P2RX3) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

P2X Purinoceptor 3 (P2RX3) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

P2X Purinoceptor 3 (P2RX3) – Companies Involved in Therapeutics Development

Asana BioSciences LLC

Bayer AG

Beijing Tide Pharmaceutical Co Ltd

BELLUS Health Inc

Future Analgesics

Integral Molecular Inc

Merck & Co Inc

Neurim Pharmaceuticals Ltd

Ossianix Inc

Shionogi & Co Ltd

Sino Biopharmaceutical Ltd

P2X Purinoceptor 3 (P2RX3) – Drug Profiles

ASN-009 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLU-5937 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eliapixant – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FA-006 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gefapixant citrate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Antagonize P2X3 Receptor for Pain – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OSX-300 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

piromelatine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sivopixant – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize P2X3 for Inflammatory Pain – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize P2X3 Receptor for Chronic Pain – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize P2X3 for Neuropathic Pain – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TCR-1672 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TDI-06 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P2X Purinoceptor 3 (P2RX3) – Dormant Products

P2X Purinoceptor 3 (P2RX3) – Discontinued Products

P2X Purinoceptor 3 (P2RX3) – Product Development Milestones

Featured News & Press Releases

Nov 01, 2021: BELLUS Health convenes virtual analyst event to discuss the chronic cough landscape and its selective P2X3 antagonist BLU-5937

Oct 08, 2021: Sino Biopharmaceutical announces IND application of innovative medicine “TCR1672” filed with and accepted by FDA

Sep 23, 2021: BELLUS Health announces completion of patient enrollment in SOOTHE phase 2b trial for refractory chronic cough and BLUEPRINT phase 2a trial for chronic pruritus associated with atopic dermatitis

Sep 13, 2021: BELLUS Health announces positive interim analysis from the phase 2b SOOTHE trial of BLU-5937 in refractory chronic cough

Sep 06, 2021: Bayer’s Eliapixant significantly decreased cough frequency in Phase IIb trial in patients with refractory chronic cough

Aug 23, 2021: BELLUS Health to report additional RELIEF data in an oral presentation at the European Respiratory Society International Congress 2021

Aug 03, 2021: Evotec SE: Positive phase IIb data for investigational P2X3 antagonist in patients with refractory chronic cough

May 10, 2021: BELLUS Health to present at the American Thoracic Society 2021 International Conference

Mar 03, 2021: MSD files refractory cough medicine in Japan

Mar 01, 2021: U.S. FDA accepts Merck’s gefapixant New Drug Application for review

Jan 14, 2021: BELLUS Health to present at the Eleventh International Virtual Cough Symposium

Dec 14, 2020: BELLUS Health announces first patient dosed in its phase 2 BLUEPRINT trial of BLU-5937 for the treatment of chronic pruritus associated with atopic dermatitis

Dec 08, 2020: BELLUS Health announces first patient dosed in its phase 2b SOOTHE trial of BLU-5937 for the treatment of refractory chronic cough

Sep 09, 2020: Merck’s gefapixant decreases chronic cough frequency in Phase III trials

Sep 08, 2020: BELLUS Health announces design for its phase 2b Ttial with BLU-5937 in refractory Chronic Cough

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Asana BioSciences LLC, 2021

Pipeline by Bayer AG, 2021

Pipeline by Beijing Tide Pharmaceutical Co Ltd, 2021

Pipeline by BELLUS Health Inc, 2021

Pipeline by Future Analgesics, 2021

Pipeline by Integral Molecular Inc, 2021

Pipeline by Merck & Co Inc, 2021

Pipeline by Neurim Pharmaceuticals Ltd, 2021

Pipeline by Ossianix Inc, 2021

Pipeline by Shionogi & Co Ltd, 2021

Pipeline by Sino Biopharmaceutical Ltd, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

Discontinued Products, 2021

Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

Frequently asked questions

P2X Purinoceptor 3 (P2RX3) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

P2X Purinoceptor 3 (P2RX3) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at P2X Purinoceptor 3 (P2RX3) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update in real time.

  • Access a live P2X Purinoceptor 3 (P2RX3) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.